

Australasian Menopause Society (AMS)



AUSTRALASIAN MENOPAUSE SOCIETY
Supporting Midlife Women

MEDIA RELEASE

For immediate release – 14 November 2025

Australian Menopause Experts Support Change in Hormone Therapy warnings

The Australasian Menopause Society (AMS) has urged women to continue seeking advice from their doctor about the possible risks of menopausal hormone therapy (MHT) in the wake of a U.S Food and Drug Administration (FDA) decision to remove the black box warning.

AMS President, Dr Christina Jang said the FDA's action acknowledges a current understanding that the risks of MHT have previously been overstated.

Dr Jang said the AMS would support a TGA review of the product and consumer information relating to MHT products in Australia.

"There are a range of MHT products available in Australia. Different formulations carry different risk profiles; for the majority of women benefits of MHT outweigh the risks"

"We don't have long term safety data for modern MHT preparations, so women should still discuss individual risks with their doctor," Dr Jang said.

"MHT is highly effective for the treatment of menopause symptoms and the decision to use MHT should be based on a discussion between the woman and her doctor considering her personal risk versus benefit profile." Dr Jang said.

The FDA imposed a black box warning on all MHT products in 2003 in the wake of headlines regarding potential risks.

About the Australasian Menopause Society

The Australasian Menopause Society (AMS) is a not-for-profit, multidisciplinary organisation dedicated to improving women's health during midlife and beyond. AMS provides education, advocacy, and professional standards for clinicians, and serves as a trusted source of menopause information across Australia and New Zealand.

www.menopause.org.au

Media contact

Chris Michaelides – Executive Director
Australasian Menopause Society
M: 0418 499 569 | E: chrism@menopause.org.au
W: www.menopause.org.au